Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.The company has 3 R&D and 5 manufacturing facilities.
What Alembic files
- Others153
- Updates64
- Investor Meet40
- Important39
- Dividend/Bonus19
- Board Meeting15
Alembic Pharma reported a strong Q1 FY27, with revenue up 26% year-over-year to INR 2,150 Cr and reported profit after tax climbing 12% YoY to INR 173 Cr. EBITDA before R&D also rose 23% YoY to INR 523 Cr, showcasing a robust 24% margin. Growth was broad-based: US Formulation revenue...
Alembic Pharmaceuticals reported a robust Q4 FY26 with revenue at 1848 Cr (+4% YoY) and full-year revenue of 7345 Cr (+10% YoY). Profit After Tax (PAT) for Q4 jumped 29% YoY to 203 Cr, while full-year PAT grew 16% to 675 Cr. Pre R&D EBITDA stood at 455 Cr (+29%...
Alembic Pharma reported strong Q3 FY26 results! Total revenue jumped 11% YoY to INR 1,876 Cr. India's branded business grew 6% to INR 652 Cr, while US Generics also increased 6% to INR 553 Cr, fueled by new launches. Ex-US Generics was a standout, hitting an all-time high with 36%...
Alembic Pharma's Q3 FY26 & 9M financial update shows robust performance in key segments. 1. **Business Performance:** International Generics led growth, with Q3 sales up 17% to 954 Cr and 9M sales up 20% to 2,754 Cr, fueled by strong gains in Australia, Europe & ROW, and Canada. The US...
Alembic Pharmaceuticals delivered a strong Q2 FY26, with revenue climbing 16% YoY to INR 1910 Cr and Net Profit surging 41% YoY to INR 185 Cr. EBIDTA also grew 26% to INR 324 Cr. Growth was broad-based: US Generics jumped 21% to INR 566 Cr driven by new product launches...